Development And Valuation Of Cancer-specific Multi-attribute Health States For Use In Economic Evaluation
Funder
National Health and Medical Research Council
Funding Amount
$707,671.00
Summary
Economic evaluation is used by the Australian government in deciding which medical services and pharmaceuticals should be funded. This study will develop quality of life utility measures for use in economic evaluation of cancer interventions in Australia and internationally. This represents a significant methodological contribution to the assessment of quality of life, effectiveness and efficiency in cancer, in one of Australia's national health priority areas.
AusGo-SHEMO….Let’s Go! Australian Gold Standard Health Economics Model Of Osteoporosis
Funder
National Health and Medical Research Council
Funding Amount
$378,959.00
Summary
We will develop an unbiased, gold standard, validated, transparent health economics model of osteoporosis to identify cost-effective screening and treatment strategies, and that will be made widely available to all stakeholders. Without this model, scarce health care resources may be squandered on osteoporosis screening strategies and osteoporosis-related fracture prevention medications that are not cost-effective. Worse, patient access to cost-effective medications may be delayed.
Modelling The Cost-effectiveness Of Therapeutic Strategies For Invasive Candidiasis Among The ICU Population
Funder
National Health and Medical Research Council
Funding Amount
$282,733.00
Summary
ICU patients are vulnerable to fungal infections during their stay in hospital. These infections are costly to treat and pose real dangers to the patient with up to 1270 lives lost each year. The best way to diagnose and treat these infections is currently not known. Making an early and accurate diagnosis is difficult but important if the infection is to be managed appropriately. This research will show which management strategies are optimal for patients and health services.
Development And Validation Of A Health Policy Simulation Model For Type 1 Diabetes.
Funder
National Health and Medical Research Council
Funding Amount
$409,199.00
Summary
This proposal brings together an international multi-disciplinary team to develop and validate a health economic computer simulation model for type 1 diabetes and its complications. It examines the impact of diabetes on costs as well as quality of life. Outcomes generated by the model will inform health policy decisions regarding allocation of resources for people with type 1 diabetes such as cost-effectiveness analysis of new treatments and technologies.
Economic Evaluation Of Alternative Pneumococcal Vaccination Strategies
Funder
National Health and Medical Research Council
Funding Amount
$242,894.00
Summary
Pneumococcal vaccination is a readily available preventive strategy that can offer substantial protection to the elderly but it is important that we carefully evaluate the different potential strategies to ensure the most (cost-) effective approach to prevention is identified. This grant will explore alternative strategies to control pneumococcal-related disease in elderly Australians using the available vaccines.
Developing An Australian Valuation For The EQ-5D-5L Quality Of Life Instrument
Funder
National Health and Medical Research Council
Funding Amount
$348,357.00
Summary
In the assessment of gains resulting from a health technology, it is standard to consider both mortality and quality of life effects. This project explores how Australians value different components of quality of life. To do this, we are running an online survey called a discrete choice experiment, and analysing the data using a range of cutting-edge econometric techniques. This will allow policy-makers to better reflect people's preferences when making decisions about new technologies.
Development And Validation Of A Health Policy Simulation Model For Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$507,910.00
Summary
The research is focused on evaluating policies associated with treating cardiovascular disease in Australia (CVD). It will involve the development of a computer simulation model for CVD which can be used to assess the cost-effectiveness of wide range of health care treatments. As prices of cardiovascular therapies after the expiry of patents, how much more widely should cardiovascular medication be prescribed? This is the type of question that can be answered through a CVD simulation model.
Increasing Population Health By Making Better Funding Decisions: Estimation Of The Cost-effectiveness Threshold For The Australian Health System
Funder
National Health and Medical Research Council
Funding Amount
$341,368.00
Summary
This project will estimate the Australian opportunity cost of decisions to fund new health care technologies, such as pharmaceuticals and medical devices. The opportunity cost represents the health benefits that could be achieved if the resources used to fund a new technology are used to fund the best alternative technology or service instead. We will then disseminate the information to decision makers, to improve funding decisions, and hence the efficiency of the Australian health care system.